- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Medscape Nets $17.3 Million Through Private Investors
The new year is already proving profitable for Medscape (formerly Medicalogic/Medscape), which has begun referring to itself as a provider of digital health record technologies (versus EMRs) and online health information. The company has signed a
The new year is already proving profitable for Medscape (formerly Medicalogic/Medscape), which has begun referring to itself as a provider of digital health record technologies (versus EMRs) and online health information. The company has signed a definitive agreement with a group of investors for a $17.3 million capital investment. The financing involves issuing 5.7 million shares of preferred stock at $3 per share, with warrants to purchase 4.4 million shares of common stock at $0.01 per share. The deal coincides with the appointment of Donald Bloodworth as Medscape's chief financial officer.
In related news, Medscape has signed its first digital health agreement, with Glaxo Wellcome. The educational initiative will create asthma-specific sites and disease management tools on medscape.com and cbshealthwatch.com, two Web sites produced by Medscape.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
